Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1)

Results from the TRINOVA-1 study of trebananib plus weekly paclitaxel versus placebo plus paclitaxel in women with recurrent ovarian cancer demonstrate that the improvement in PFS among patients in the trebananib arm was achieved without compromising HRQoL.

from Cancer via ola Kala on Inoreader http://ift.tt/25xyOu5
via IFTTT